On Sunday, June 2, at 3:30 p.m. ET, insitro CEO and founder Daphne Koller will join other scientists, technologists and artists for the Spring Into Science series at the #WorldScienceFestival in New York City. The panel titled “Fundamental Science in the Age of Artificial Intelligence” will feature Daphne alongside author Brian Greene, Microsoft’s Eric Horvitz and Wolfram’s Stephen Wolfram for a conversation exploring the profound role #AI is poised to play in taking human understanding to the next level. For more on the event, visit the link below.
insitro
Biotechnology Research
South San Francisco, California 23,840 followers
Making medicines differently to bring better drugs faster to the patients who benefit most with ML and data at scale.
About us
insitro is a data-driven drug discovery and development company that leverages machine learning and high-throughput biology to transform the way medicines are created to help patients. At insitro, we are rethinking the entire drug discovery process, from the perspective of machine learning, human genetics, and high-throughput, quantitative biology. Over the past five decades, we have seen the development of new medicines becoming increasingly more difficult and expensive, leaving many patients with significant unmet need. We’re embarking on a new approach to drug development – one that leverages machine learning and unique in vitro strategies for modeling disease state and designing new therapeutic interventions. We aim to eliminate key bottlenecks in traditional drug discovery, so we can help more people sooner and at a much lower cost to the patient and the healthcare industry. We believe that by harnessing the power of technology to interrogate and measure human biology, we can have a major impact on many diseases. We invest heavily in cutting edge bioengineering technologies to enable the construction of large-scale, high-quality data sets that are designed specifically to drive machine learning methods. Our first application is to use human genetics, functional genomics, and machine learning to build a new generation of in vitro human cell-derived disease models whose response to perturbation is designed to be predictive of human clinical outcomes. This cannot be done without great people. We are bringing together an outstanding team of people whose expertise spans multiple disciplines - life sciences, machine learning, human genetics, engineering, and drug discovery - and building a unique culture where people from diverse backgrounds work as a single team towards a common goal. We offer opportunities to collaborative people with expertise in life science and computational science. Join us to help bring better health to more people, faster and cheaper.
- Website
-
http://www.insitro.com
External link for insitro
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Privately Held
- Founded
- 2018
- Specialties
- biotech, machine learning, data science, drug development, science, and life science
Locations
-
Primary
Get directions
259 E Grand Ave
South San Francisco, California 94080, US
Employees at insitro
Updates
-
We were thrilled to welcome #AI and #machinelearning visionary Emily Fox to our team earlier this spring! Thank you Ron Leuty and San Francisco Business Times for sitting down with Emily and Daphne Koller to discuss the impact her appointment will have on our team, the progress being made at insitro, and how we are leaning into the combination of technology, biology, and data at scale to drive intentional #drugdiscovery that will transform future treatment for patients. Read more below:
How Insitro’s big hires help it push AI drug discovery - San Francisco Business Times
bizjournals.com
-
insitro CFO and CBO, Mary Rozenman, Ph.D., will be at Biocom California’s Converge Summit today for a session titled, “Executive Insights: A Fireside Chat.” Mary will share her perspective, alongside industry leader Margo Georgiadis of Montai Therapeutics and Flagship Pioneering as they reflect on the journey of building companies at the intersection of biology, technology, and therapeutics and explore what the future might hold. Register for the event and learn more: https://lnkd.in/gcY6ZkES
-
-
“In parallel to the AI revolution that was visible to many… there was a revolution that I think is not quite as visible to the general public – which is that of [new] tools in the life sciences that enable the creation of massive data at scale.” insitro founder and CEO, Daphne Koller recently joined CPP Investments | Investissements RPC to share insights she’s learned from building insitro, as well as the inspiration and goals behind her vision of combining #machinelearning and #AI with human and cellular biologic data at scale. Listen below for more from Daphne on the evolution of #AI and how insitro operates within this unique ecosystem to drive innovation for patients.
Daphne Koller founded insitro with the audacious goal to use the power of AI to revolutionize drug discovery. Don’t miss her interview with Paul McCracken, Managing Director Growth Equity and Nadeem Janmohamed , Managing Director Active Equities North America, in the latest edition of the Insights Institute newsletter. https://lnkd.in/g4pemRfp
-
Join insitro founder and CEO, Daphne Koller for a panel moderated by Matt Herper at STAT’s Breakthrough Summit West where she’ll share her perspective on how to best set expectations for #AI in drug development. Daphne will be joined by Derek Lowe of Novartis and insitro board member Vijay Pande, PhD, of a16z Bio + Health to engage in a conversation as they explore what AI could mean for advancing the drug development process as we know it at 4:45 p.m. PT today. Register here: https://lnkd.in/eVthzRYF #STATBreakthrough
-
-
#ICYMI: insitro CEO and founder Daphne Koller was at the Milken Institute’s #MIGlobal Conference last week to discuss the “golden age in medicine” with Noubar Afeyan, Aloe Blacc, Samarth Kulkarni and Pablo Legorreta, moderated by Alice Park of TIME. Catch the full panel below as they discuss #AI’s promise to accelerate the development of new treatments and cures and the many innovations that stand to revolutionize healthcare.
Panel - Placing New Bets in Biomedical Innovation: Where Is the Next Cure? | Milken Institute
milkeninstitute.org
-
insitrocyte Srinivasan Sivanandan, Senior Machine Learning Scientist, will be at #ICLR24 this week presenting, "Channel Vision Transformer: An Image Is Worth 1 x 16 x 16 Words," which was published alongside Yujia Bao and Theofanis Karaletsos. Vision Transformer (ViT), a “powerful architecture in the realm of modern computer vision,” sets the benchmark for image representation. However, unique challenges arise when using ViTs in highly multiplexed imaging settings with sparse availability of channels such as microscopy and satellite imaging. In response to these challenges, we introduced ChannelViT and Hierarchical Channel Sampling (HCS) as modifications to the traditional ViT architecture. The novel modification presented provides greater interpretability, powerful regularization and robustness when only a subset of the imaging channels are available. We demonstrate the improved performance of ChannelViT on ImageNet, microscopy cell imaging, and satellite imaging. For more details, be sure to check out our poster presentation Wednesday, May 8 at 10:45 a.m. CEST in Vienna, Austria. Learn more: https://lnkd.in/ehi4gr9G
-
-
insitro Founder and CEO, Daphne Koller, is at the Milken Institute’s #MIGlobal Conference for the panel conversation, “Placing New Bets in Biomedical Innovation: Where is the Next Cure?” Daphne will offer her expert insights alongside fellow industry leaders Noubar Afeyan, Aloe Blacc, Samarth Kulkarni and Pablo Legorreta as they discuss the “golden age in medicine,” and what it will bring in groundbreaking advancements that will shape the future for patients, health systems, and governments. Register and join us: https://lnkd.in/djvDh6F9
-
-
We are privileged to welcome #AI and #machinelearning visionary, Emily Fox, PhD, to insitro as our Senior Vice President of AI/ML. Emily will lead AI, machine learning, data science and computational biology, inclusive of data modalities that span genetics, omics, imaging, clinical data, and molecular design. She brings deep experience and groundbreaking contributions to the application of machine learning in healthcare, driving meaningful impact to patients. AI leaders of Emily’s caliber who simultaneously have an understanding of biology and health are rare, and we are privileged to have recruited her to lead our AI/ML teams. Currently a professor in the Department of Statistics and Department of Computer Science at Stanford University, Emily has had an influential career, including leading the Health AI team at Apple and serving as the Amazon Professor of Machine Learning in the Paul G. Allen School of Computer Science & Engineering and Department of Statistics at the University of Washington. From partnering with our executive team to leading our world class machine learning and data science teams to closely collaborating with our software engineering teams, we’re eager to leverage Emily’s tremendous expertise as we continue to build our platform and advance our pipeline towards the clinic. Read more about Emily’s experience, including thoughts from Daphne Koller and AI pioneer Fei-Fei Li, in the release here: https://lnkd.in/dKgbpxgD
-
Our chief scientific officer Philip Tagari recently joined a16z Bio + Health’s Vijay Pande, PhD for an exciting conversation on his multi-decade journey in drug discovery and the role #AI and data at scale are playing in moving from “hunting for” drugs to engineering safe and effective therapeutics. Take a listen below.
"We're in this transition from finding [drugs] to designing [drugs]" - Philip Tagari, CSO at insitro. Phil recently joined Vijay Pande, PhD, founding general partner at a16z Bio+Health, to discuss all things drug discovery and AI including: 👉🏼 the evolution of drug discovery methods 👉🏼 the opportunity for scalable personalized medicine 👉🏼 and how Phil transitioned his career from the laboratory, to major biopharma companies, and now to a startup environment. Listen on Raising Health: https://lnkd.in/gfmAMEzZ None of the information discussed should be taken as investment advice; please see https://lnkd.in/gjmYWkHi for more information.
-